114 results
10-K
2022 FY
OBSVF
ObsEva SA
31 Mar 23
Annual report
4:01pm
million, on an annual basis, of cash compensation related to salary, bonus, and benefits to affected employees. In February 2023, as part … a risk evaluation and mitigation strategy (“REMS”), to help ensure that the benefits of the drug outweigh the potential risks. REMS can include
F-3
EX-4.2
OBSVF
ObsEva SA
9 Dec 22
Shelf registration (foreign)
7:06am
Mutilated, Destroyed, Lost or Stolen Securities
Section 2.08
Cancellation
Section 2.09
Benefits of Indenture
Section 2.10
Authenticating Agent
Section 2.11 … that the Security so authenticated has been duly authenticated and delivered hereunder and that the holder is entitled to the benefits of this Indenture. At any
F-3
EX-4.1
OBSVF
ObsEva SA
9 Dec 22
Shelf registration (foreign)
7:06am
, ou par l’émission d’actions nouvelles.
Compensation may be paid in the form of cash or in the form of other types of benefits. It can be paid … of the compensation.
Article 33: Prêts, crédits et prestations de prévoyance
Article 33: Loans, credits and retirement benefits
Sous réserve de l’article 34 para. 5
F-3
OBSVF
ObsEva SA
9 Dec 22
Shelf registration (foreign)
7:06am
, against contributions in kind or for the purpose of acquiring specific assets and granting specific benefits;
limiting or withdrawing shareholder’s pre … , pension benefits not based on occupational pension schemes and performance-based compensation not provided for in the articles of association
6-K
EX-99.2
OBSVF
ObsEva SA
1 Dec 22
Index to Unaudited Condensed Consolidated Financial Statements
4:15pm
represents estimated cash compensation related to salary, bonus, and benefits to affected employees.
On October 20, 2022, we attended the first … salaries, benefits and share-based compensation expenses for our employees; expenses related to regulatory affairs and intellectual property
6-K
s02bq xkiz7wi0ft4
1 Dec 22
Index to Unaudited Condensed Consolidated Financial Statements
4:15pm
6-K
EX-99.3
gx51xn
1 Dec 22
Index to Unaudited Condensed Consolidated Financial Statements
4:15pm
6-K
EX-99.1
bvwyzr5i3d
1 Dec 22
Index to Unaudited Condensed Consolidated Financial Statements
4:15pm
6-K
EX-99.2
x0bto4 j2dlkz4h8zsm7
22 Nov 22
Consent and Amendment Agreement
7:10am
6-K
EX-99.2
7hrd7673
26 Oct 22
ObsEva Announces Progress on Cost Reduction Initiatives and Stay of
5:11pm
6-K
EX-99.1
hp0avqc2b31zwv7b9gys
13 Sep 22
ObsEva Announces Progress on Restructuring Initiatives
9:13am
6-K/A
EX-99.1
d0z7gs7m
13 Sep 22
Index to Unaudited Condensed Consolidated Financial Statements
9:08am
6-K
EX-99.1
vt1d 0swzxidiut6ycx9
17 Aug 22
Index to Unaudited Condensed Consolidated Financial Statements
4:01pm
6-K
EX-99.2
5q3a soet7sa
17 Aug 22
Index to Unaudited Condensed Consolidated Financial Statements
4:01pm
6-K
EX-99.1
s9br 09h3jx830
27 Jul 22
ObsEva Announces Corporate Updates
7:03am
6-K
EX-99.1
74l myjw27
28 Jun 22
ObsEva Announces UK MHRA Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
4:13pm
6-K
EX-99.1
fhnknr4cij0dl6l
17 Jun 22
ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
7:05am
6-K
EX-99.1
t14ox
17 May 22
Index to Unaudited Condensed Consolidated Financial Statements
7:00am
6-K
EX-99.3
lge36rv1h40xjc3c
17 May 22
Index to Unaudited Condensed Consolidated Financial Statements
7:00am
6-K
EX-99.2
qnn0yr1n 6f9
17 May 22
Index to Unaudited Condensed Consolidated Financial Statements
7:00am